Literature DB >> 33433642

Assessment of ocular surface disease in glaucoma patients with benzalkonium chloride-preserved latanoprost eye drops: a short-term longitudinal study.

Chien-Chia Su1,2,3, Yi-Chieh Lee4, Peter Richmond Candano Lee5.   

Abstract

PURPOSE: To prospectively evaluate the effect of benzalkonium chloride (BAK)-preserved latanoprost on ocular surface damage and identify the associated risk factors among treatment-naive glaucoma patients.
METHODS: The basal Schirmer's test results, corneal Oxford staining score, non-invasive keratograph tear-breakup time, oculus hyperemia index score (objective metrics), and ocular surface disease index (OSDI) questionnaire (subjective metric) were evaluated at baseline, 1 month, and 4 months after receiving latanoprost eye drops. Associated risk factors were assessed by multivariate linear regression.
RESULTS: Seventy-four eyes (44 patients) were enrolled. Basal Schirmer's test tear-flow and Oxford scores gradually deteriorated (β = -0.14, P = 0.001 and β = 0.1, P < 0.001, respectively). The percentage of unstable tear-film (breakup time < 10 s) increased significantly at 4 months (6.21% vs 9.11%, P = 0.042). Hyperemic scores increased significantly at 1 month and normalized at 4 months (P = 0.01 and P = 0.16, respectively); total OSDI scores tended to improve (β = -0.76, P = 0.06). Older age was associated with additional corneal Oxford staining (P = 0.005); female sex was associated with increased unstable tear-film scores (P = 0.01). Artificial tear use was associated with a smaller decrease in basal Schirmer's test values (P = 0.01) and a smaller increase in unstable tear-film scores (P = 0.02).
CONCLUSIONS: Preserved latanoprost eye drops affected ocular surface changes in glaucoma patients through decreased basal tear secretion. Artificial tears represent an early intervention in vulnerable glaucoma patients with reduced tear secretion and impaired tear-film stability.

Entities:  

Keywords:  Benzalkonium chloride (BAK)-preserved latanoprost; Glaucoma; Ocular surface damage

Mesh:

Substances:

Year:  2021        PMID: 33433642     DOI: 10.1007/s00417-020-05067-y

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.535


  29 in total

1.  Use of Topical Intraocular Pressure-lowering Medications in the US Population: Results From the NHANES Study 1999 to 2014.

Authors:  Eugene A Lowry; Sunee Chansangpetch; Shan C Lin
Journal:  J Glaucoma       Date:  2019-09       Impact factor: 2.503

2.  Prevalence of ocular surface complaints in patients with glaucoma using topical intraocular pressure-lowering medications.

Authors:  Robert D Fechtner; David G Godfrey; Donald Budenz; Jeanette A Stewart; William C Stewart; Mark C Jasek
Journal:  Cornea       Date:  2010-06       Impact factor: 2.651

3.  Prevalence of signs and symptoms of ocular surface disease in individuals treated and not treated with glaucoma medication.

Authors:  Sudipta Ghosh; Fleur O'Hare; Ecosse Lamoureux; Rasik B Vajpayee; Jonathan G Crowston
Journal:  Clin Exp Ophthalmol       Date:  2012-06-04       Impact factor: 4.207

4.  Ocular Surface Disease in Patients under Topical Treatment for Glaucoma.

Authors:  Francisco Pérez-Bartolomé; Jose M Martínez-de-la-Casa; Pedro Arriola-Villalobos; Cristina Fernández-Pérez; Vicente Polo; Julián García-Feijoó
Journal:  Eur J Ophthalmol       Date:  2017-11-08       Impact factor: 2.597

5.  Reliability and validity of the Ocular Surface Disease Index.

Authors:  R M Schiffman; M D Christianson; G Jacobsen; J D Hirsch; B L Reis
Journal:  Arch Ophthalmol       Date:  2000-05

Review 6.  Dry eye disease: the scale of the problem.

Authors:  H Brewitt; F Sistani
Journal:  Surv Ophthalmol       Date:  2001-03       Impact factor: 6.048

7.  Evaluation of ocular surface disease in patients with glaucoma.

Authors:  Priya M Mathews; Pradeep Y Ramulu; David S Friedman; Canan A Utine; Esen K Akpek
Journal:  Ophthalmology       Date:  2013-05-25       Impact factor: 12.079

8.  Prevalence of ocular surface disease in glaucoma patients.

Authors:  Eamon W Leung; Felipe A Medeiros; Robert N Weinreb
Journal:  J Glaucoma       Date:  2008-08       Impact factor: 2.503

Review 9.  Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis.

Authors:  Yih-Chung Tham; Xiang Li; Tien Y Wong; Harry A Quigley; Tin Aung; Ching-Yu Cheng
Journal:  Ophthalmology       Date:  2014-06-26       Impact factor: 12.079

10.  Challenges in the clinical measurement of ocular surface disease in glaucoma patients.

Authors:  Stephen C Pflugfelder; Christophe Baudouin
Journal:  Clin Ophthalmol       Date:  2011-11-01
View more
  1 in total

1.  A multicenter prospective comparative study evaluating cataract surgery and endoscopic cyclophotocoagulation either with or without iStent inject implantation in Brazilian patients with glaucoma.

Authors:  Francisco E Lima; João C Geraissate; Marcos P Ávila
Journal:  Int Ophthalmol       Date:  2022-10-23       Impact factor: 2.029

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.